Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07829783) titled 'A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)' on Sept. 15.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Merck Sharp & Dohme LLC
Condition:
Bladder Cancer
Intervention:
Biological: Sac-TMT
Biological: Pembrolizumab and Berahyaluronidase alfa
Drug: Cisplatin
Drug: 5-FU
Drug: MMC
Drug: Capecitabine
Drug: Gemcitabine
Radiation: Conventional Radiotherapy
Radiation: Hypofractionated radiot...